Ask HopeStage to review this study with me
Study ID: NCT00182078. We help you review the study, but cannot decide medical eligibility.
CompletedNCT00182078
Sertraline to Prevent PTSD
This study is completed in the United States. It is testing sertraline for PTSD.
PTSD, DepressionDrugFrom 6 Years to 20 Years
Key information made simple
What is this study testing?
This study is testing whether Sertraline may be useful for people experiencing ptsd.
What would participation involve?
Participants may receive Sertraline, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for people with ptsd. Because it may involve minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Completed
- Estimated enrollment
- 26
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- PHASE4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 20 Years
- Official registry ID
- NCT00182078
- Official title
- A Study of Sertraline to Prevent PTSD
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT00182078. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: The broad, long-term objectives of this proposal are to prevent the emergence of posttraumatic stress and depressive symptoms in children admitted for an acute burn, reconstructive surgery, or non-burn injury. This study is investigating the early use of a medication in the. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving Placebo, Sertraline. The listed phase is PHASE4. Ask the study team what that means in practice for safety, monitoring, and criteria.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
Does a loved one or caregiver need to be involved?
The public registry appears to mention a loved one, caregiver, or family involvement. Ask whether that person must participate, provide information, attend visits, or simply be available if needed. The study team must confirm what is required.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Massachusetts General Hospital, which appears to be a hospital or academic medical center. Sponsor website: https://www.massgeneralbrigham.org. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join. The registry lists an estimated enrollment of 26 participants.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01861847
7-Keto DHEA for PTSD
This study is completed. It focuses on PTSD and currently lists study information in the United States.
CompletedNCT03508700
TNX-102 SL 5.6 mg Taken Daily at Bedtime for PTSD
This study is completed in the United States. It is testing TNX-102 SL 5.6 mg Taken Daily at Bedtime for PTSD.
CompletedNCT00554177
A study for PTSD
This study is completed. It focuses on PTSD and currently lists study information in the United States.